AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas. PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2). RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response. CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.
AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas. PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2). RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastomapatients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response. CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.
Entities:
Keywords:
alternative regimens; chemotherapy; glioblastoma; glioma temodar; safety; temozolomide
Authors: E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: K Vera; L Djafari; S Faivre; J-S Guillamo; K Djazouli; M Osorio; F Parker; C Cioloca; B Abdulkarim; J-P Armand; E Raymond Journal: Ann Oncol Date: 2004-01 Impact factor: 32.976
Authors: David E Piccioni; Julia Selfridge; Reema R Mody; Reshmi Chowdhury; Sichen Li; Shadi Lalezari; James Wawrzynski; Jennifer Quan; Mira Zurayk; Arthur P Chou; Desiree E Sanchez; Linda M Liau; Benjamin M Ellingson; Whitney B Pope; Phioanh L Nghiemphu; Richard M Green; He-Jing Wang; William H Yong; Robert Elashoff; Timothy F Cloughesy; Albert Lai Journal: Neuro Oncol Date: 2014-03-13 Impact factor: 12.300
Authors: A W Tolcher; S L Gerson; L Denis; C Geyer; L A Hammond; A Patnaik; A D Goetz; G Schwartz; T Edwards; L Reyderman; P Statkevich; D L Cutler; E K Rowinsky Journal: Br J Cancer Date: 2003-04-07 Impact factor: 7.640
Authors: Augusto Leone; Antonio Colamaria; Nicola Pio Fochi; Matteo Sacco; Matteo Landriscina; Giovanni Parbonetti; Matteo de Notaris; Giulia Coppola; Elena De Santis; Guido Giordano; Francesco Carbone Journal: Biomedicines Date: 2022-08-09